Posiflex Announces Android 10 Google Mobile Services Certification for Kiosk Platforms
23.2.2021 06:00:00 EET | Business Wire | Press release
Posiflex Technology, Inc., a world leader in the design and manufacture of retail POS, kiosk, computing, and self-service transaction peripherals, is proud to announce a new Android 10 GMS certification, applicable to the kiosk portfolio of both Posiflex and KIOSK Information Systems (KIOSK).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005417/en/
Powered by POSIFLEX, Certified with GMS (Graphic: Business Wire)
Posiflex CEO Owen Chen notes, “This new Android 10 GMS certification milestone is quite significant. By offering GMS Certified kiosks, it allows Google Play and other GMS applications to be installed on our Android platforms. It streamlines onboarding onto Google’s proven and secure network, while unlocking kiosk access to the full suite of applications in the Google Play Store.”
Further, as mobile devices become increasingly pervasive in delivering retail and hospitality services, corporate Mobile Device Management (MDM) platforms rely on Android or iOS compatibility to optimize efficiencies within an edge device management ecosystem. Not a problem when considering mobile devices and tablets, but robust kiosk solutions require greater durability and significantly more ability to house transaction peripherals than are provided on commercial Android tablet devices. The Android 10 GMS certified kiosk platforms are equipped with ample computing and enough USB ports to power a kiosk platform with multiple integrated transaction peripherals.
KIOSK President Kim Kenney adds, “We have seen an increased demand among major retailers and hospitality clients for Android GMS capability to access Google Play Services to register and manage their kiosk fleet within their existing infrastructure. Through the certification efforts of the Posiflex R&D Team, both KIOSK and Posiflex can now provide best-in-class self-service features that can be consistently managed through existing Android OS networks. Without question, this provides niche competitive advantage and enables us to uniquely meet important new market requirements.”
About Posiflex Group, Inc.
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell, further expanding into self-service and embedded PC offerings. The global Posiflex Group is in place to provide world-class B2B Serviced IoT solutions. For more information: www.posiflex.com
About KIOSK Information Systems
KIOSK provides self-service automation solutions to increase operational and cost efficiencies, while enhancing the customer experience. With over 27 years of experience and >250,000+ kiosks deployed, the company is a trusted digital transformation partner for Top 100 Retailers and Fortune 500 clients. KIOSK delivers proven expertise in design engineering and manufacturing, application development, integration, and comprehensive support services. An innovative portfolio of self-service solutions paired with managed services and IoT capabilities ensure a seamless user experience. Learn more at kiosk.com, 800.509.5471.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005417/en/
Contact information
Posiflex Group Press Contact (Taiwan): Brad Chou, marketing@posiflex.com.tw
KIOSK Press Contact (US): Cheryl Madeson, VP Marketing and Communications, cmadeson@kiosk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom